Literature DB >> 16515568

Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.

K N Gaarenstroom1, B van der Hiel, R A E M Tollenaar, G R Vink, F W Jansen, C J van Asperen, G G Kenter.   

Abstract

The outcome of screening and prophylactic surgery in 269 women at high risk of hereditary ovarian cancer is reported. Screening was performed using transvaginal ultrasound and serum CA125 testing. Mean follow-up was 26 months (583 person-years). A total of 113 (42%) of 269 women had a pathogenic BRCA1 or BRCA2 mutation, and 127 (47%) of 269 women underwent salpingo-oophorectomy. No occult cancers were found. In eight women having both elevated CA125 levels and abnormal ultrasound findings, a malignancy was found. Four of these cancers (one borderline, one stage Ia, one stage IIIb, and one stage IIIc ovarian or peritoneal cancer) were detected at the first screening visit. One stage IIIb and one stage IIIc cancer were detected at the second screening visit after 12 months, and two interval stage IIIc and IV cancers were detected 8 and 10 months after the first screening visit. No peritoneal carcinoma was found among those 114 women who underwent bilateral salpingo-oophorectomy with normal or benign pathology results, after a mean follow-up of 16 months (152 person-years). We conclude that the efficacy of screening women at high risk of ovarian cancer seems poor because the majority of cancers were detected at an advanced stage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515568     DOI: 10.1111/j.1525-1438.2006.00480.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

Review 1.  The clinical management of BRCA1 and BRCA2 mutation carriers.

Authors:  Anthony P Gulati; Susan M Domchek
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

2.  Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome.

Authors:  Kaylene J Ready; Molly S Daniels; Charlotte C Sun; Susan K Peterson; Hope Northrup; Karen H Lu
Journal:  J Cancer Educ       Date:  2010-09       Impact factor: 2.037

3.  A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.

Authors:  Carolyn Y Fang; Carol Cherry; Karthik Devarajan; Tianyu Li; John Malick; Mary B Daly
Journal:  Gynecol Oncol       Date:  2009-01-13       Impact factor: 5.482

4.  Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

Authors:  Gabriel N Mannis; Julia E Fehniger; Jennifer S Creasman; Vanessa L Jacoby; Mary S Beattie
Journal:  JAMA Intern Med       Date:  2013-01-28       Impact factor: 21.873

Review 5.  Management of genetic syndromes predisposing to gynecologic cancers.

Authors:  Susan Miesfeldt; Amanda Lamb; Christine Duarte
Journal:  Curr Treat Options Oncol       Date:  2013-03

Review 6.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

7.  Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Authors:  Adam N Rosenthal; Lindsay Fraser; Ranjit Manchanda; Philip Badman; Susan Philpott; Jessica Mozersky; Richard Hadwin; Fay H Cafferty; Elizabeth Benjamin; Naveena Singh; D Gareth Evans; Diana M Eccles; Steven J Skates; James Mackay; Usha Menon; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

8.  Endometrial and ovarian cancer in lynch syndrome.

Authors:  Marta Ann Crispens
Journal:  Clin Colon Rectal Surg       Date:  2012-06

9.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

10.  The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Authors:  Patrick O Brown; Chana Palmer
Journal:  PLoS Med       Date:  2009-07-28       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.